Previous 10 | Next 10 |
home / stock / scyx / scyx articles
NEW YORK, Jan. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEX...
NEW YORK, Dec. 29, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXI...
NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds invest...
NEW YORK, Dec. 26, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXI...
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, not...
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXI...
If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and September 22, 2023 and would like to discuss ...
SAN DIEGO, Dec. 16, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons...
NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXI...
News, Short Squeeze, Breakout and More Instantly...
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024 Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal infections remain on track for delivery to GSK in mid 2024, which would...